Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade

Key Points

• Needham raised Vaxcyte’s price target from $110 to $122 while maintaining a Buy rating, contributing to unusually heavy trading volume. The stock was last quoted at $65.31, below its prior close of $73.82.
• Vaxcyte reported that its VAX-31 vaccine candidate met all primary endpoints in the pivotal OPUS-1 Phase 3 trial, supporting optimism about its potential in the adult pneumococcal vaccine market. Analysts maintain a broadly positive outlook, with a consensus rating of Moderate Buy and a $108.60 price target.
• The company launched proposed offerings totaling approximately $1 billion in common stock, pre-funded warrants and convertible notes, which could fund development but may dilute existing shareholders and increase financing obligations.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham & Company LLC raised their price target on the stock from $110.00 to $122.00. Needham & Company LLC currently has a buy rating on the stock. 1,142,393 shares changed hands during mid-day trading, a decline of 21% from the previous session's volume of 1,454,975 shares. The stock last traded at $65.3120 and had previously closed at $73.82.

A number of other brokerages have also commented on PCVX. Wall Street Zen raised shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Bank of America lowered their price target on Vaxcyte from $133.00 to $130.00 and set a "buy" rating on the stock in a research note on Monday, September 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Friday. Zacks Research raised Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Finally, Guggenheim upped their target price on Vaxcyte from $116.00 to $125.00 and gave the company a "buy" rating in a research note on Monday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $108.60.

Insider Buying and Selling

In other news, insider Harpreet Dhaliwal sold 17,000 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the sale, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. This represents a 18.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the transaction, the chief financial officer owned 105,176 shares of the company's stock, valued at $5,667,934.64. This trade represents a 8.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 55,890 shares of company stock valued at $3,111,189 over the last ninety days. Company insiders own 3.30% of the company's stock.

Key Headlines Impacting Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: VAX-31 met all prespecified primary endpoints in the pivotal OPUS-1 adult Phase 3 trial across the age groups studied, with immune responses comparable to Prevnar 20 and/or Capvaxive. The broader 31-valent coverage strengthens Vaxcyte’s potential positioning in the adult pneumococcal vaccine market. Vaxcyte Reports Positive Topline Data from OPUS-1
• Positive Sentiment: Analysts viewed the late-stage success as a potential “blue-sky” outcome. Jefferies estimated the addressable adult market could reach roughly $3 billion to $6 billion or more, while Needham raised its price target from $110 to $122 and BTIG reaffirmed a Buy rating with an $89 target. Vaxcyte Given New Price Target at Needham
• Neutral Sentiment: Trading activity reflected heightened optimism and speculation, including above-average call-option purchases and renewed attention to Vaxcyte’s competitive prospects in the pneumococcal vaccine market.
• Negative Sentiment: Vaxcyte launched separate offerings for approximately $500 million of common stock and pre-funded warrants and $500 million of convertible senior notes due 2032, with potential over-allotments. The capital could fund development and commercialization, but the equity issuance may dilute existing holders and the convertible debt adds future financing complexity. Vaxcyte Announces Proposed Public Offerings

Hedge Funds Weigh In On Vaxcyte

Institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC bought a new stake in shares of Vaxcyte during the second quarter valued at approximately $1,044,355,000. BlackRock Inc. bought a new position in Vaxcyte in the 2nd quarter worth approximately $701,520,000. Janus Henderson Group PLC raised its position in shares of Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company's stock worth $960,231,000 after acquiring an additional 3,188,687 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company's stock valued at $521,213,000 after buying an additional 2,981,038 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company's stock valued at $407,001,000 after buying an additional 1,386,968 shares during the period. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Performance

The company has a fifty day moving average price of $59.04 and a two-hundred day moving average price of $56.31. The company has a market cap of $9.87 billion, a P/E ratio of -8.61 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period last year, the business posted ($1.22) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte's lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.